Table 6. Prediction of All-SGA, Normotensive-SGA and Hypertensive-SGA based on clinical risk factors at 15±1 weeks’ combined with ultrasound factors at 20±1 weeks’ gestation in a nulliparous cohort using cut-offs at 5%, 10%, and 25% false positive rates.
| No (%) with abnormal test result | Sensitivity | Specificity | PPV | NPV | Positive Likelihood ratio | Negative Likelihood ratio |
| All-SGA Validation cohort | ||||||
| 114 (6.2%) | 15 (11 to 20) | 95 (94 to 96) | 27 (20 to 36) | 90 (89 to 91) | 3.0 (2.0 to 4.4) | 0.90 (0.84 to 0.94) |
| 218 (11.8%) | 26 (21 to 32) | 90 (89 to 91) | 24 (19 to 30) | 91 (90 to 91) | 2.6 (1.9 to 3.4) | 0.83 (0.76 to 0.89) |
| 517 (27.9%) | 52 (45 to 58) | 75 (74 to 76) | 21 (18 to 23) | 93 (92 to 94) | 2.1 (1.7 to 2.4) | 0.65 (0.56 to 0.74) |
| Normotensive-SGA Validation cohort | ||||||
| 109 (5.9%) | 16 (10 to 23) | 95 (94 to 96) | 21 (14 to 30) | 93 (92 to 94) | 3.1 (2.0 to 4.8) | 0.89 (0.83 to 0.95) |
| 217 (11.7%) | 31 (23 to 39) | 90 (88 to 91) | 21 (16 to 27) | 94 (92 to 95) | 3.1 (2.3 to 4.1) | 0.77 (0.69 to 0.86) |
| 505 (27.3%) | 53 (45 to 61) | 75 (73 to 77) | 15 (12 to 19) | 95 (94 to 96) | 2.1 1.8 to 2.5) | 0.63 (0.53 to 0.74) |
| Hypertensive SGA Validation cohort | ||||||
| 111 (6.0%) | 34 (22 to 47) | 95 (94 to 96) | 18 (12 to 27) | 98 (97 to 98) | 6.7 (4.4 to 10.0) | 0.70 (0.58 to 0.84) |
| 206 (11.1%) | 44 (31 to 58) | 90 (88 to 91) | 13 (9 to 18) | 98 (97 to 99) | 4.4 (3.2 to 6.0) | 0.62 (0.50 to 0.78) |
| 492 (26.6%) | 71 (58 to 82) | 75 (73 to 77) | 9 (6 to 11) | 99 (98 to 99) | 2.8 (2.4 to 3.4) | 0.38 (0.26 to 0.57) |